KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. PMID 41710044 · Rheumatol Adv Pract · 2026 The study is a randomized Phase 3 trial with a drug intervention (bimekizumab) and reports original results, but it is not an oncology trial (psoriatic arthritis) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoints are patient-reported outcomes (EQ-5D-3L) and work productivity (WPAI-SHP), which are not time-to-event survival outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial. PMID 41709925 · Ther Adv Med Oncol · 2026 The trial is explicitly a randomized, multicenter, noninferiority study with PFS as primary endpoint and OS as key secondary, meeting definitive Phase III-like criteria for oncology drug intervention. The report is an original journal article with efficacy results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
A Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial. PMID 41701010 · Pharm Stat · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. PMID 41694241 · Can J Kidney Health Dis · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Actigraphy-Quantified Physical Activity Measurements in Patients with Symptomatic LMNA-Related Dilated Cardiomyopathy in REALM-Dilated Cardiomyopathy. PMID 41693767 · Digit Biomark · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acupuncture combined with immunotherapy for recurrent and metastatic cervical cancer: a pilot RCT protocol. PMID 41684588 · Front Oncol · 2026 The record is a protocol for a randomized trial in cervical cancer, which meets oncology, human, randomized, and drug intervention criteria. However, it does not present results; it is a protocol. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III (it is described as a 'pilot' and 'first' RCT, which does not establish definitive-phase evidence). The primary endpoint (ORR) is not a time-to-event endpoint, though PFS and OS are listed as secondary endpoints. Therefore, it is excluded as a protocol without results and due to unclear phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials. PMID 41669379 · Ther Adv Med Oncol · 2026 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG). PMID 41662245 · PLoS One · 2026 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China. PMID 41625476 · Cancer Commun (Lond) · 2026 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 4 Panel · risk unclear
KRAS p.G12C mutated-targeted treatments in metastatic colorectal cancer: a systematic review and meta-analysis. PMID 41612983 · Ann Gastroenterol · 2026 The record is a systematic review and meta-analysis of multiple early-phase trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial. The abstract does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. PMID 41610103 · PLoS One · 2026 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes after Surgery for Proliferative Vitreoretinopathy: Post hoc Analysis of a Randomized Controlled Trial. PMID 41610080 · Ophthalmologica · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Digital health interventions for cervical cancer screening among hard-to-reach women in health-resource-limited areas: Protocol for a controlled trial with historical controls and two randomised intervention arms. PMID 41602939 · Digit Health · 2026 This is a protocol for a randomized controlled trial evaluating a digital health intervention (web/WeChat platform) for cervical cancer screening, not a drug intervention. It reports no efficacy results (Kaplan-Meier, HR, time-to-event endpoints) and is a Phase not specified as III/IIIb or II/III. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41589575 · Integr Cancer Ther · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Topical Tofacitinib for Atopic Dermatitis - Outcomes from Randomized Phase 3 Clinical Trial: First Approval. PMID 41585823 · Indian J Dermatol · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia: A Meta-Analysis of Randomized Controlled Trials. PMID 41542285 · Cardiovasc Ther · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Determinants of publication likelihood and timeliness for clinical studies. PMID 41536814 · J Clin Transl Sci · 2026 The record is a meta-analytical study of factors predicting publication timeliness for clinical trials, not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event endpoint. It lacks the specific trial results required.
S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. PMID 41531249 · Helicobacter · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions. PMID 41526135 · Handb Clin Neurol · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. PMID 41522368 · Alzheimers Dement (N Y) · 2026 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial. PMID 41519383 · Asia Pac J Ophthalmol (Phila) · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103. PMID 41494910 · Brachytherapy · 2026 The study is a randomized trial with a primary time-to-event endpoint (biochemical failure) for human prostate cancer. However, it fails the drug intervention criterion because the intervention is brachytherapy (a radioisotope treatment), not a systemic drug therapy. The phase of the trial is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, but even if it were, the absence of a drug intervention makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology. PMID 41461224 · Ophthalmol Glaucoma · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma. PMID 41453647 · Ann Hepatol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115). PMID 41428603 · Oncol Res Treat · 2026 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Study on the Improvement of Quality of Survival in Cervical Cancer Patients after Chemoradiotherapy through an Integrated Traditional Chinese and Western Medicine Therapy Based on a Syndrome Differentiation-Driven Dynamic Intervention Strategy. PMID 41343416 · Oncology · 2026 The study is a randomized oncology trial reporting primary OS results via Kaplan-Meier and Cox regression, but the intervention is a non-drug-only regimen (integrated Chinese and Western medicine therapy without specified drug-containing component), and the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. PMID 41287969 · CA Cancer J Clin · 2026 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 5 Panel · risk unclear
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis. PMID 41189512 · Dermatitis · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Translated article] Network meta-analysis of perioperative immunotherapies in non-small-cell lung cancer according to tumor programmed death ligand 1 expression. PMID 41188103 · Farm Hosp · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis. PMID 41140764 · Gastro Hep Adv · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials. PMID 41093262 · Prog Cardiovasc Dis · 2026 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial. PMID 40906605 · Ann Nutr Metab · 2026 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors. PMID 40784346 · Psychother Psychosom · 2026 The study is an oncology randomized controlled trial reporting original results, but it is ineligible because it lacks a drug intervention and its primary endpoint is not a time-to-event efficacy measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Volumetric Changes and Acute Toxicity With 68Ga Prostate-Specific Membrane Antigen Versus 18F-Fluciclovine Positron Emission Tomography/Computer Tomography Guided Postprostatectomy Radiation: Final Analysis of a Randomized Trial. PMID 40738247 · Pract Radiat Oncol · 2026 The report is a primary, randomized, human oncology trial, but it is excluded because it lacks a time-to-event efficacy endpoint and does not involve a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study. PMID 40652928 · Acta Haematol · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis. PMID 40152029 · Dermatitis · 2026 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bayesian model averaging for randomized dose optimization trials in multiple indications. PMID 39930766 · J Biopharm Stat · 2026 The record describes a statistical methodology paper proposing a Bayesian model averaging approach for dose optimization in randomized Phase III trials. While it references oncology, humans, randomization, and Phase III, it does not report or analyze any clinical trial results with a time-to-event efficacy endpoint. It is a simulation study, not an original clinical trial result report.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combination of Danggui Buxue Tang and concurrent chemoradiotherapy improves treatment outcomes by strengthening B cell immunity in patients with nasopharyngeal carcinoma-a double-blind, randomized trial. PMID 41158262 · Transl Cancer Res · 2025-Sep-30 The record is a randomized trial in human oncology with a drug intervention, but it fails two key eligibility criteria: 1) it does not establish a definitive Phase III/IIIb or Phase II/III designation (the phase is unspecified, but the small sample size and primary endpoint suggest an early-phase exploratory trial), and 2) it lacks a time-to-event efficacy endpoint. The primary endpoint is adverse effects and compliance, which is a safety/tolerability endpoint, not an efficacy endpoint. The secondary endpoints focus on TCM constitution and gene expression, with no mention of survival or progression-free time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41150411 · Vaccines (Basel) · 2025-Sep-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase III Clinical Trial of Immunogenicity and Safety of Meningococcal A and C Polysaccharide Conjugate Vaccine in Infants Aged 3-5 Months. PMID 41150410 · Vaccines (Basel) · 2025-Sep-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study. PMID 41133003 · Transl Lung Cancer Res · 2025-Sep-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Aspirin on Development of First and Recurrent Primary Cutaneous Keratinocyte Carcinomas in Older Australian Adults: Extended Follow-up of a Large Randomised Controlled Trial. PMID 41112419 · J Cancer Prev · 2025-Sep-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of liposomal bupivacaine combined with bupivacaine hydrochloride for transversus thoracic muscle plane block and pectoral nerves block in modified radical mastectomy for breast cancer: protocol for a randomised controlled trial. PMID 41033778 · BMJ Open · 2025-Sep-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Investigation of prophylactic clip haemorrhage control for colorectal cold snare polypectomy in patients taking antithrombotic drugs (PERCOLD): study protocol-a multicentre prospective parallel-group non-inferiority RCT phase 3 trial. PMID 41033774 · BMJ Open · 2025-Sep-30 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Postoperative bladder training in patients with mid-low rectal cancer facilitates early removal of the urinary catheter: a prospective, randomized, open-label, blinded-endpoint trial. PMID 41029750 · World J Surg Oncol · 2025-Sep-30 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China. PMID 41029430 · BMC Health Serv Res · 2025-Sep-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Exit interviews with caregivers of pediatric patients with classic galactosemia to explore meaningfulness of changes in the ACTION-galactosemia kids trial. PMID 41029344 · Orphanet J Rare Dis · 2025-Sep-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer. PMID 41028776 · Sci Rep · 2025-Sep-30 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial. PMID 41027700 · BMJ Open · 2025-Sep-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis. PMID 41024315 · Hereditas · 2025-Sep-29 The study is a randomized trial in humans with a primary clinical endpoint, but it is not an oncology study (severe acute pancreatitis). The intervention is a non-drug procedure (blood purification/hemodiafiltration). No time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis is reported.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -